论文部分内容阅读
目的探讨米非司酮治疗子宫肌瘤的临床疗效及安全性。方法选择子宫肌瘤患者176例,在月经周期第1天开始每日空腹顿服米非司酮12.5 g,3个月为1个疗程,用药期间每月监测患者的肝、肾功能,治疗前后进行B超检查。结果治疗后患者子宫体积和子宫肌瘤体积较治疗前明显缩小(P<0.05),贫血大多得以纠正,血红蛋白上升,不良反应轻。结论米非司酮治疗子宫肌瘤有较好的临床效果,不良反应少,是一种理想的药物治疗方法。
Objective To investigate the clinical efficacy and safety of mifepristone in treating uterine fibroids. Methods A total of 176 patients with uterine myoma were enrolled in this study. Day 1 of the menstrual cycle began daily fasting with mifepristone 12.5 g for 3 months for one course of treatment. The liver and kidney function of the patients was monitored monthly for the duration of treatment. B ultrasound examination. Results After treatment, the volume of uterine fibroids and the volume of uterine fibroids were significantly reduced (P <0.05), the anemia was mostly corrected, hemoglobin increased, and the adverse reactions were mild. Conclusion Mifepristone treatment of uterine fibroids have better clinical results, fewer adverse reactions, is an ideal drug treatment.